|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
60,190,000 |
Market
Cap: |
334.66(M) |
Last
Volume: |
1,702,056 |
Avg
Vol: |
1,686,122 |
52
Week Range: |
$3.39 - $9.95 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 5.8 |
Insider 3/6 Months : 6.4 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Anavex Life Sciences is a clinical stage biopharmaceutical company engaged in the development of therapeutics by applying medicine to central nervous system (CNS) diseases. Co.'s primary compound, ANAVEX®2-73, is being developed to treat Alzheimer's disease, Parkinson's disease and other CNS diseases, including rare diseases, such as Rett syndrome. Co.'s proprietary SIGMACEPTOR Discovery Platform produced small molecule drug candidates with certain modes of action, based on its understanding of sigma receptors. Compounds that have been subjects of Co.'s research include the following: ANAVEX®3-71, ANAVEX®1-41, ANAVEX®1066, and ANAVEX®1037.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
7,835 |
7,835 |
7,835 |
Total Buy Value |
$0 |
$32,919 |
$32,919 |
$32,919 |
Total People Bought |
0 |
2 |
2 |
2 |
Total Buy Transactions |
0 |
2 |
2 |
2 |
Total Shares Sold |
0 |
73,380 |
73,380 |
341,380 |
Total Sell Value |
$0 |
$374,972 |
$374,972 |
$2,514,282 |
Total People Sold |
0 |
1 |
1 |
1 |
Total Sell Transactions |
0 |
1 |
1 |
2 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Thomas Steffen |
Director |
|
2024-05-15 |
4 |
B |
$4.52 |
$22,600 |
D/D |
5,000 |
5,000 |
2.39 |
26% |
|
Missling Christopher U |
President and CEO |
|
2024-03-28 |
4 |
S |
$5.11 |
$374,972 |
D/D |
(73,380) |
1,250,210 |
|
-30% |
|
Missling Christopher U |
President and CEO |
|
2024-03-28 |
4 |
OE |
$1.32 |
$96,862 |
D/D |
73,380 |
1,323,590 |
|
- |
|
Missling Christopher U |
President and CEO |
|
2023-06-29 |
4 |
OE |
$1.60 |
$371,200 |
D/D |
232,000 |
1,250,210 |
|
- |
|
Missling Christopher U |
President and CEO |
|
2023-06-28 |
4 |
S |
$7.98 |
$2,139,310 |
D/D |
(268,000) |
1,018,210 |
|
24% |
|
Missling Christopher U |
President and CEO |
|
2023-06-28 |
4 |
OE |
$1.60 |
$428,800 |
D/D |
268,000 |
1,286,210 |
|
- |
|
Skarpelos Athanasios |
Director |
|
2022-05-25 |
4 |
S |
$9.06 |
$453,000 |
D/D |
(50,000) |
1,306,458 |
|
- |
|
Skarpelos Athanasios |
Director |
|
2022-05-25 |
4 |
OE |
$0.92 |
$46,000 |
D/D |
50,000 |
1,356,458 |
|
- |
|
Boenisch Sandra |
PFO and Treasurer |
|
2021-06-29 |
4 |
S |
$26.53 |
$4,422,445 |
D/D |
(166,696) |
22,963 |
|
- |
|
Boenisch Sandra |
PFO and Treasurer |
|
2021-06-29 |
4 |
OE |
$3.28 |
$699,163 |
D/D |
166,696 |
189,659 |
|
- |
|
Missling Christopher U |
President and CEO |
|
2021-06-29 |
4 |
S |
$26.00 |
$1,342,120 |
D/D |
(51,620) |
1,018,210 |
|
- |
|
Missling Christopher U |
President and CEO |
|
2021-06-29 |
4 |
OE |
$1.32 |
$68,138 |
D/D |
51,620 |
1,069,830 |
|
- |
|
Favus Elliot |
Director |
|
2021-05-21 |
4 |
S |
$11.70 |
$1,696,283 |
D/D |
(145,000) |
0 |
|
- |
|
Favus Elliot |
Director |
|
2021-05-21 |
4 |
OE |
$0.92 |
$280,820 |
D/D |
145,000 |
145,000 |
|
- |
|
Donhauser Peter D.o. |
Director |
|
2021-05-17 |
4 |
B |
$10.93 |
$10,930 |
D/D |
1,000 |
2,165 |
2.39 |
- |
|
Favus Elliot |
Director |
|
2021-02-24 |
4 |
S |
$12.66 |
$1,841,855 |
D/D |
(145,500) |
0 |
|
- |
|
Favus Elliot |
Director |
|
2021-02-24 |
4 |
OE |
$2.58 |
$445,390 |
D/D |
145,500 |
145,000 |
|
- |
|
Donhauser Peter D.o. |
Director |
|
2021-02-19 |
4 |
B |
$12.62 |
$14,760 |
D/D |
1,165 |
1,165 |
2.39 |
- |
|
Missling Christopher U |
President and CEO |
|
2018-03-07 |
4 |
AB |
$2.92 |
$3,971 |
D/D |
1,360 |
1,018,210 |
|
- |
|
Missling Christopher U |
President and CEO |
|
2018-03-06 |
4 |
AB |
$2.73 |
$3,959 |
D/D |
1,450 |
1,016,850 |
|
- |
|
Missling Christopher U |
President and CEO |
|
2018-03-05 |
4 |
AB |
$2.63 |
$3,945 |
D/D |
1,500 |
1,015,400 |
|
- |
|
Missling Christopher U |
Director, President & CEO |
|
2018-03-02 |
4 |
AB |
$2.41 |
$3,977 |
D/D |
1,650 |
1,013,900 |
|
- |
|
Missling Christopher U |
President and CEO |
|
2017-10-25 |
4 |
AB |
$4.39 |
$1,646 |
D/D |
375 |
1,012,250 |
|
- |
|
Missling Christopher U |
President and CEO |
|
2017-10-24 |
4 |
AB |
$4.92 |
$1,845 |
D/D |
375 |
1,011,875 |
|
- |
|
Missling Christopher U |
President and CEO |
|
2017-10-19 |
4 |
AB |
$4.49 |
$1,684 |
D/D |
375 |
1,011,500 |
|
- |
|
58 Records found
|
|
Page 1 of 3 |
|
|